AU2002236569A1 - Treatment of cancer by reduction of intracellular energy and pyrimidines - Google Patents

Treatment of cancer by reduction of intracellular energy and pyrimidines

Info

Publication number
AU2002236569A1
AU2002236569A1 AU2002236569A AU3656902A AU2002236569A1 AU 2002236569 A1 AU2002236569 A1 AU 2002236569A1 AU 2002236569 A AU2002236569 A AU 2002236569A AU 3656902 A AU3656902 A AU 3656902A AU 2002236569 A1 AU2002236569 A1 AU 2002236569A1
Authority
AU
Australia
Prior art keywords
pyrimidines
cancer
reduction
treatment
intracellular energy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002236569A
Inventor
Joseph R Bertino
Jason Koutcher
Daniel S. Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sloan Kettering Institute for Cancer Research
Original Assignee
Sloan Kettering Institute for Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Institute for Cancer Research filed Critical Sloan Kettering Institute for Cancer Research
Publication of AU2002236569A1 publication Critical patent/AU2002236569A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002236569A 2000-12-04 2001-12-04 Treatment of cancer by reduction of intracellular energy and pyrimidines Abandoned AU2002236569A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25099300P 2000-12-04 2000-12-04
US60250993 2000-12-04
PCT/US2001/046886 WO2002045720A1 (en) 2000-12-04 2001-12-04 Treatment of cancer by reduction of intracellular energy and pyrimidines

Publications (1)

Publication Number Publication Date
AU2002236569A1 true AU2002236569A1 (en) 2002-06-18

Family

ID=22950034

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002236569A Abandoned AU2002236569A1 (en) 2000-12-04 2001-12-04 Treatment of cancer by reduction of intracellular energy and pyrimidines

Country Status (4)

Country Link
EP (1) EP1349555A4 (en)
AU (1) AU2002236569A1 (en)
CA (1) CA2436847A1 (en)
WO (1) WO2002045720A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7381713B2 (en) 2000-12-04 2008-06-03 Sioan-Kettering Institute For Cancer Research Treatment of cancer by reduction of intracellular energy and pyrimidines
GB2530479A (en) * 2014-08-06 2016-03-30 Hilmar Meek Warenius Peptides useful for treating cancer
WO2017062352A1 (en) * 2015-10-06 2017-04-13 Rensselaer Polytechnic Institute Controlled drug release from electrospun fibers
GB201602409D0 (en) * 2016-02-10 2016-03-23 Warenius Hilmar M Compositions and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
CA2136091A1 (en) * 1992-05-20 1993-11-25 Daniel S. Martin Chemotherapeutic drug combinations

Also Published As

Publication number Publication date
EP1349555A1 (en) 2003-10-08
WO2002045720A1 (en) 2002-06-13
EP1349555A4 (en) 2007-04-25
CA2436847A1 (en) 2002-06-13

Similar Documents

Publication Publication Date Title
AU2001288432A1 (en) Materials and methods to potentiate cancer treatment
AU7735200A (en) Treatment of tissue by application of energy and drugs
AU2001282717A1 (en) Cancer treatment by combination therapy
AUPR406501A0 (en) Treatment of vault prolapse
AU2002320058A1 (en) Magnetic-nanoparticle conjugates and methods of use
AU2002223599A1 (en) Pyrimidinone derivatives and their use in the treatment of atherosclerosis
AU2002258399A1 (en) Use of trail and antiprogestins for treating cancer
AUPQ923100A0 (en) Treatment of prostate cancer
AUPQ877300A0 (en) Topical treatment of skin
AU2001268525A1 (en) Human kinases
AU2001222215A1 (en) Lumbago treating girdle
AU2002236569A1 (en) Treatment of cancer by reduction of intracellular energy and pyrimidines
AU2001251747A1 (en) Flavedo powder enhancement of orange juice
AU2001261375A1 (en) Human caspase-12 materials and methods
AU2002213174A1 (en) Treatment of apoptotic cell death
AU2001241779A1 (en) Method of treatment of prostate cancer
AU2002215111A1 (en) Ruthenium-aryl-compounds in cancer therapy
AU2001276462A1 (en) Use of natural products in cancer treatment
AU2002217984A1 (en) Erythropoietin and erythropoietin receptor expression in human cancer
AU2001255573A1 (en) Human kinases
AU5552400A (en) Treatment of cancer
AUPQ367699A0 (en) Treatment of cancer
AU2001257325A1 (en) Cancer treatment
AU2002366195A1 (en) Use of bisindolmaleimide and gemcitabine for the treatment of cancer
AU2002242705A1 (en) Utilization of buprenorphine in urinary incontinence therapy